Navigation Links
e-Zassi.com Provides Industry With Online U.S. FDA Regulatory Calculator for Rapid Medical Device Technology Assessment
Date:10/20/2009

FERNANDINA BEACH, Fla., Oct. 20 /PRNewswire/ -- e-Zassi.com, the fast-growing provider of the medical device industry's first secure online decision-support and industry network, has released its powerful U.S. Regulatory Calculator as a stand-alone tool available at $375 at www.e-Zassi.com to give users an analysis of the FDA classification of up to three separate medical technologies along with a one-year membership in the e-Zassi medical device industry network.

e-Zassi.com was developed as an online industry network to allow everyone across the spectrum of medical device industry to search, match, collaborate and analyze technologies, individuals and organizations using the most advanced decision-support search engine platform that uniquely fosters deeper levels of information sharing while also protecting members from over-disclosure issues that could negatively impact intellectual properties.

The e-Zassi.com U.S. Regulatory Calculator

The e-Zassi.com U.S. Regulatory Calculator is proprietary software powered by a current database of information on classified medical devices. Anyone involved with medical devices - from researchers to engineers, technology transfer agents, business development officers, medical device companies and investors - can use the new FDA Regulatory Calculator by inputting non-confidential product attributes and physical details about their new product or technology. The e-Zassi.com U.S. Regulatory Calculator searches and provides the potential predicate codes and other critical regulatory information in just minutes, rather than more than two months, which is often how long it takes for the U.S. Food and Drug Administration to determine a product's classification.

"Because many products don't fit neatly into existing classifications, this process is often a complex and confusing first step when designing a product or making a submission to the FDA," said e-Zassi Chief Executive Officer Peter M. von Dyck, who holds numerous patents and has commercialized many new medical device technologies. Von Dyck explains that: "Not knowing the potential FDA classification early on can adversely skew the entire development, clinical trials, commercialization and capitalization plans. Understanding and navigating the regulatory environment and classification that a newer medical technology will need to conform to is one of the most essential elements of any development and commercialization plan and without this information early and throughout the development process you are in essence developing in the dark."

About e-Zassi.com

e-Zassi.com is a subscription-based online community and Software as a Service (SaaS) company that was spun off Zassi Medical Evolutions®, a privately held company with more than a decade innovating and developing in medical devices. The full suite of software tools on e-Zassi.com supports those in the medical device industry, from product development through manufacturing and distribution. Tools allow for technology transfer; business development; market and commercial analysis; due diligence & portfolio management; intellectual property and patent development; product development and financial planning; and capital acquisition via venture capital and grants. Customized memberships are available now. For more information regarding e-Zassi.com or to join the Network, please visit www.e-zassi.com or call +1.866.474.6328.

SOURCE e-Zassi.com


'/>"/>
SOURCE e-Zassi.com
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
3. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
4. Raptor Pharmaceuticals Provides Update of Product Programs
5. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
6. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
7. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
11. Improved Cornea Surgery Technique Provides Enhanced Transplant Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
Breaking Medicine News(10 mins):